Filing summary
Entity mismatch: The supplied filing is Galena Biopharma, Inc.’s Form 10-Q, not a filing by SELLAS Life Sciences Group, Inc. It covers the quarter and six months ended June 30, 2013, and was signed August 9, 2013. Amounts below are in U.S. dollars; financial statement amounts are rounded to millions unless noted.
Business context
Galena was a development-stage biopharmaceutical company pursuing cancer therapies. Its lead candidate, NeuVax, was in a Phase 3 breast cancer trial; FBP was in Phase 1/2 trials. Galena had acquired U.S. rights to the FDA-approved cancer-pain product Abstral in March 2013 and was preparing a U.S. commercial launch planned for the fourth quarter of 2013. It had recorded no product revenue through June 30.
Key financial metrics
| Metric | Q2 / June 30, 2013 | Comparable period / prior year-end |
|---|---|---|
| Revenue | None | None reported for Q2 2012 |
| Net loss | Q2: $9.6m; six months: $18.9m | Q2 2012: $0.2m loss; first half 2012: $25.0m loss |
| Research and development expense | Q2: $5.3m; six months: $10.4m | Q2 2012: $3.7m; first half 2012: $6.4m |
| General and administrative expense | Q2: $2.7m; six months: $4.2m | Q2 2012: $2.0m; first half 2012: $3.7m |
| Cash used in operating activities | Six months: $12.5m | First half 2012: $11.6m |
| Cash and cash equivalents | $20.9m | $32.8m at December 31, 2012 |
| Marketable securities | $5.8m | $2.7m at December 31, 2012 |
| Total debt | $9.7m, including $0.3m current | No long-term debt reported at December 31, 2012 |
| Total assets / liabilities / equity | $62.0m / $46.8m / $15.2m | At December 31, 2012: $55.0m / $27.2m / $27.8m |
Current assets were $27.5m and current liabilities $25.8m, implying working capital of about $1.8m. Profitability and operating margins were not meaningful given the absence of revenue and ongoing losses.
Material changes versus comparable periods
- Q2 net loss widened by about $9.4m from Q2 2012, reflecting higher operating expenses and a swing in other income, including changes in the fair value of liability-classified warrants.
- First-half net loss improved by about $6.1m year over year, primarily because the prior-year period had larger warrant-related noncash expense; R&D spending increased as the NeuVax Phase 3 trial ramped up.
- First-half R&D expense rose 62% to $10.4m, mainly due to the PRESENT trial. G&A increased to $4.2m, partly from building the Abstral sales organization.
- Cash declined by $11.9m from year-end. Operating use and the $10.0m Abstral rights payment were partly offset by $9.9m net proceeds from new debt.
- Liabilities rose, including a $14.9m fair-value liability for potentially cash-settleable warrants and $9.7m of new long-term debt. Marketable securities were RXi shares; their value is subject to share-price changes.
Outlook, risks and unusual items
- Management expected existing working capital to fund operations into the second quarter of 2014. It could seek the remaining $5.0m debt tranche, subject to conditions, and acknowledged that additional funding might be needed and might not be available on acceptable terms.
- Abstral launch was planned for Q4 2013. Galena had no commercialization track record and expected increased expenses before meaningful product revenue. The Orexo agreement includes a $5.0m cash milestone recorded in accrued liabilities, future sales-based milestones and royalties, and a minimum sales-force obligation; failure to meet that obligation could permit Orexo to reacquire U.S. rights without payment.
- The first $10.0m debt tranche carries an 8.45% fixed rate, 12 months of interest-only payments, then 30 months of principal and interest amortization, plus a 5.5% final payment. The additional $5.0m tranche is conditional.
- Key risks include NeuVax clinical-trial and regulatory outcomes, Abstral adoption and reimbursement, competition from branded and generic products, controlled-substance and DEA quota requirements, third-party manufacturing and supply, and the company’s ability to raise capital. The filing also describes dependence on a sole source of Leukine for NeuVax trials.
- After quarter-end, RXi completed a 1-for-30 reverse split. Galena reported selling additional RXi shares through August 8 for net proceeds of $0.7m and held shares valued at approximately $3.4m on that date.
Important facts for investors to verify
- Confirm the intended issuer: this filing identifies Galena Biopharma, not SELLAS Life Sciences Group.
- Track actual Abstral launch timing, revenue, reimbursement access, sales-force compliance, and the $5.0m milestone payment.
- Verify cash burn and financing runway against the stated expectation of funding into Q2 2014, including availability of the conditional debt tranche.
- Monitor NeuVax PRESENT trial enrollment and results, and the progress of the NeuVax combination and FBP trials.
- Review the valuation and potential cash-settlement exposure of the warrant liability, as well as RXi share value and any related sales.